Trial · NCT04617171
Benralizumab Initiated During Severe Asthma Attack
NCT04617171, Phase 2, Unknown, Singapore General Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Benralizumab Initiated During Severe Asthma Attack. Trials, record NCT04617171. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04617171
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Benralizumab Initiated During Severe Asthma Attack
- NCT number
- NCT04617171
- Status
- Unknown
- Phases
- Phase 2
- Enrollment
- 128 participants, estimated
- Lead sponsor
- Singapore General Hospital
- Conditions
- Asthma Attack, Asthma
- Interventions
- Benralizumab 30 MG/ML [Fasenra], Placebos
- First posted
- 2020-11-05
- Last updated
- 2021-07-23
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time to first exacerbation in patients with a severe asthma exacerbation with raised blood eosinophil count | Change from baseline (Day 1) to 52 weeks | Time to first exacerbation requiring either oral corticosteroid (OCS) use and/or an unscheduled visit to the Emergency Department or hospitalization |
| Secondary | Time to hospital readmission due to asthma exacerbation (Key Secondary outcome) | Baseline (Day 1) to 52 weeks | Time to hospital readmission due to asthma exacerbation |
| Secondary | Rate of severe exacerbation (i.e. requiring admission to hospital for asthma exacerbation) | Baseline (Day 1) to 52 weeks | NUmber of severe exacerbation (i.e. requiring admission to hospital for asthma exacerbation) |
| Secondary | Hospital LOS (index admission and subsequent admissions) | Change from baseline (Day 1) to 52 weeks | Total hospital LOS |
| Secondary | Need for Intensive Care Unit (ICU) admission with/without mechanical ventilation during the index admission | Baseline (Day 1) to index admission discharge date | ICU admission during index admission |
| Secondary | Hospital survival post admission (index admission) | Baseline (Day 1) to index admission discharge date | Hospital survival for index admission |
| Secondary | Total OCS burden | Baseline (Day 1) to 52 weeks | Cumulative OCS dose |
| Secondary | Total number of exacerbations requiring emergency healthcare utilization (including ED, polyclinic visits, Specialist outpatient visits) | Baseline (Day 1) to 52 weeks | Total number of emergency healthcare utilization for exacerbations |
| Secondary | Pre/post bronchodilator Forced Expiratory Volume 1s (FEV1), FVC, FEV1/FVC at baseline and at 52 weeks | Change from baseline (Day 1) to 52 weeks | Change in Pre/post bronchodilator Forced Expiratory Volume 1s (FEV1), FVC, FEV1/FVC |
| Secondary | Blood eosinophil counts (serial measurement over 52 weeks) | Change from baseline (Day 1) to 52 weeks | Change in blood eosinophils |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04617171
GET https://conductscience.org/api/trials/v1/NCT04617171/registered